Tumor heterogeneity: does it matter?

References

• Jamal-Hanjani M, Quezada SA, Larkin J, et al. Translational implications of tumor heterogeneity. Clin Cancer Res. 2015;21:1258–1266.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339:1546–1558.
   PubMed Web of Science ®Google Scholar
• Wang J, Ma Y, Cooper MK. Cancer stem cells in glioma: challenges and opportunities. Transl Cancer Res. 2013;2:429–441.
   PubMed Web of Science ®Google Scholar
• Nowell PC. The clonal evolution of tumor cell populations. Science (New York, N.Y.). 1976;194:23–28.
   PubMed Web of Science ®Google Scholar
• Huntly BJP, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer. 2005;5:311–321.
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–737.
   PubMed Web of Science ®Google Scholar
• Yeung TM, Gandhi SC, Wilding JL, et al. Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci U S A. 2010;107:3722–3727.
   PubMed Web of Science ®Google Scholar
• Jimeno A, Feldmann G, Suarez-Gauthier A, et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther. 2009;8:310–314.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Zhou H, Liu Q, et al. Prognostic value of the expression of cancer stem cell-related markers CD133 and CD44 in hepatocellular carcinoma: from patients to patient-derived tumor xenograft models. Oncotarget. 2016;7:47431–47443.
   PubMedGoogle Scholar
• Whittle JR, Lewis MT, Lindeman GJ, et al. Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res. 2015;17:17.
   PubMed Web of Science ®Google Scholar
• Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012;10:717–728.
   PubMed Web of Science ®Google Scholar
• Valent P, Bonnet D, De Maria R, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer. 2012;12:767–775.
   PubMed Web of Science ®Google Scholar
• Schwitalla S, Fingerle AA, Cammareri P, et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell. 2013;152:25–38.
   PubMed Web of Science ®Google Scholar
• Sottoriva A, Kang H, Ma Z, et al. A big bang model of human colorectal tumor growth. Nat Genet. 2015;47:209–216.
   PubMed Web of Science ®Google Scholar
• Sun R, Hu Z, Curtis C. Big bang tumor growth and clonal evolution. Cold Spring Harb Perspect Med. 2018;8(5):a028381.
   Web of Science ®Google Scholar
• Onitilo AA, Engel JM, Greenlee RT, et al. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7:4–13.
   PubMedGoogle Scholar
• Phipps AI, Buchanan DD, Makar KW, et al. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer. 2013;108:1757–1764.
   PubMed Web of Science ®Google Scholar
• Trpkov K, Grignon DJ, Bonsib SM, et al. Handling and staging of renal cell carcinoma. Am J Surg Pathol. 2013;37:1505–1517.
   PubMed Web of Science ®Google Scholar
• Bonert M, Huang KC, Trpkov K. Handling, sampling and stage evaluation of renal cell carcinoma: a practical guide. Diagn Histopathol. 2016;22:57–64.
   Google Scholar
• Zhong Q, Rüschoff JH, Guo T, et al. Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity. Sci Rep. 2016;6:24146.
   PubMed Web of Science ®Google Scholar
• Ståhl PL, Salmén F, Vickovic S, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016;353:78–82.
   PubMed Web of Science ®Google Scholar
• Salmén F, Ståhl PL, Mollbrink A, et al. Barcoded solid-phase RNA capture for spatial transcriptomics profiling in mammalian tissue sections. Nat Protoc. 2018;13:2501–2534.
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–892.
   PubMed Web of Science ®Google Scholar
• McCroskey Z, Sim SJ, Selzman AA, et al. Primary collision tumors of the kidney composed of oncocytoma and papillary renal cell carcinoma: A review. Ann Diagn Pathol. 2017;29:32–36.
   PubMed Web of Science ®Google Scholar
• Warren A, Griffiths D, Fleming S Standards and dataset for histopathological reporting of adult renal parenchyma neoplasms [Internet]. 2017 [cited 2019 May 10]. Available from: https://www.rcpath.org/uploads/assets/uploaded/22496153-93f9-4004-87021102dc32ac6c.pdf.
   Google Scholar
• Haffner MC, Mosbruger T, Esopi DM, et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest. 2013;123:4918–4922.
   PubMed Web of Science ®Google Scholar
• Pekar G, Gere M, Tarjan M, et al. Molecular phenotype of the foci in multifocal invasive breast carcinomas: intertumoral heterogeneity is related to shorter survival and may influence the choice of therapy. Cancer. 2014;120:26–34.
   PubMed Web of Science ®Google Scholar
• Seol H, Lee HJ, Choi Y, et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol. 2012;25:938–948.
   PubMed Web of Science ®Google Scholar
• Bartlett AI, Starcyznski J, Robson T, et al. Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. Am J Clin Pathol. 2011;136:266–274.
   PubMed Web of Science ®Google Scholar
• Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med. 2009;133:611–612.
   PubMed Web of Science ®Google Scholar
• Rini B, Goddard A, Knezevic D, et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol. 2015;16:676–685.
   PubMed Web of Science ®Google Scholar
• Andor N, Graham TA, Jansen M, et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med. 2016;22:105–113.
   PubMed Web of Science ®Google Scholar
• Birkbak NJ, Eklund AC, Li Q, et al. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res. 2011;71:3447–3452.
   PubMed Web of Science ®Google Scholar
• Hawkins RA, Killen E, Tesdale AL, et al. Oestrogen receptors, lactate dehydrogenase and cellularity in human breast cancer. Clin Chim Acta. 1988;175:89–96.
   PubMed Web of Science ®Google Scholar
• Moriarity A, O’Sullivan J, Kennedy J, et al. Current targeted therapies in the treatment of advanced colorectal cancer: a review. Ther Adv Med Oncol. 2016;8:276–293.
   PubMed Web of Science ®Google Scholar
• Díaz-Serrano A, Gella P, Jiménez E, et al. Targeting EGFR in lung cancer: current standards and developments. Drugs. 2018;78:893–911.
   PubMed Web of Science ®Google Scholar
• Ali R, Arshad J, Palacio S, et al. Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy. Drug Des Devel Ther. 2019;13:569–580.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–1037.
   PubMed Web of Science ®Google Scholar
• Mulet-Margalef N, Garcia-del-Muro X. Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives. Onco Targets Ther. 2016;9:7573–7582.
   PubMed Web of Science ®Google Scholar
• Duda DG, Batchelor TT, Willett CG, et al. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med. 2007;13:223–230.
   PubMed Web of Science ®Google Scholar
• Diaz LA, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486:537–540.
   PubMed Web of Science ®Google Scholar
• Gore ME, Larkin JMG. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer. 2011;104:399–406.
   PubMed Web of Science ®Google Scholar
• Filho OM, Viale G, Trippa L, et al. HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: results from a prospective clinical trial. J Clin Oncol. 2019 [cited 2019 Jul 29];37(suppl; abstr 502). [Internet].
   Google Scholar
• Westin JR, Kurzrock R. It’s about time: lessons for solid tumors from chronic myelogenous leukemia therapy. Mol Cancer Ther. 2012;11:2549–2555.
   PubMed Web of Science ®Google Scholar
• Yates LR, Campbell PJ. Evolution of the cancer genome. Nat Rev Genet. 2012;13:795–806.
   PubMed Web of Science ®Google Scholar
• Peppercorn J. Toward improved understanding of the ethical and clinical issues surrounding mandatory research biopsies. J Clin Oncol. 2013;31:1–2.
   PubMed Web of Science ®Google Scholar
• Hagemann IS, Devarakonda S, Lockwood CM, et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer. 2015;121:631–639.
   PubMed Web of Science ®Google Scholar
• Lim C, Tsao MS, Le LW, et al. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer†. Ann Oncol. 2015;26:1415–1421.
   PubMed Web of Science ®Google Scholar
• Snyder MW, Kircher M, Hill AJ, et al. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell. 2016;164:57–68.
   PubMed Web of Science ®Google Scholar
• Bowling M, Mattingley J, Bhadra K, et al. PS01.16: shortening time from diagnosis to treatment in NSCLC: are blood-based biopsies the answer? J Thorac Oncol. 2016;11:S278–S279.
   Web of Science ®Google Scholar
• Murtaza M, Dawson S-J, Pogrebniak K, et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun. 2015;6:8760.
   PubMed Web of Science ®Google Scholar
• Yu SCY, Lee SWY, Jiang P, et al. High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. Clin Chem. 2013;59:1228–1237.
   PubMed Web of Science ®Google Scholar
• Yong E. Cancer biomarkers: written in blood. Nature. 2014;511:524–526.
   PubMedGoogle Scholar
• Gao Y, Zhang K, Xi H, et al. Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: a meta-analysis. Oncotarget. 2017;8:6330–6340.
   PubMed Web of Science ®Google Scholar
• Goodall J, Mateo J, Yuan W, et al. Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov. 2017;7:1006–1017.
   PubMed Web of Science ®Google Scholar
• Russo M, Siravegna G, Blaszkowsky LS, et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov. 2016;6:147–153.
   PubMed Web of Science ®Google Scholar
• Siravegna G, Lazzari L, Crisafulli G, et al. Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer. Cancer Cell. 2018;34:148–162.e7.
   PubMed Web of Science ®Google Scholar
• Sumanasuriya S, Lambros MB, de Bono JS. Application of liquid biopsies in cancer targeted therapy. Clin Pharmacol Ther. 2017;102:745–747.
   PubMed Web of Science ®Google Scholar
• Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285–291.
   PubMed Web of Science ®Google Scholar
• Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973–977.
   PubMed Web of Science ®Google Scholar
• Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532–536.
   PubMed Web of Science ®Google Scholar
• Turke AB, Zejnullahu K, Wu Y-L, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010;17:77–88.
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011;17:1616–1622.
   PubMed Web of Science ®Google Scholar
• Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2:117–125.
   PubMed Web of Science ®Google Scholar
• Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343:189–193.
   PubMed Web of Science ®Google Scholar
• Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of clinical oncology clinical practice guideline update. J Clin Oncol. 2017;35:3484–3515.
   PubMed Web of Science ®Google Scholar
• Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378:113–125.
   PubMed Web of Science ®Google Scholar
• Kim H, Zheng S, Amini SS, et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015;25:316–327.
   PubMed Web of Science ®Google Scholar
• Foo J, Michor F. Evolution of acquired resistance to anti-cancer therapy. J Theor Biol. 2014;355:10–20.
   PubMed Web of Science ®Google Scholar
• Zahreddine H, Borden KLB. Mechanisms and insights into drug resistance in cancer. Front Pharmacol. 2013;4:28.
   PubMed Web of Science ®Google Scholar
• Yardley DA. Drug resistance and the role of combination chemotherapy in improving patient outcomes. Int J Breast Cancer. 2013;2013:137414.
   PubMedGoogle Scholar
• Ullah MF. Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac J Cancer Prev. 2008;9:1–6.
   PubMed Web of Science ®Google Scholar
• Gatenby RA, Silva AS, Gillies RJ, et al. Adaptive Therapy. Cancer Res. 2009;69:4894–4903.
   PubMed Web of Science ®Google Scholar
• Enriquez-Navas PM, Kam Y, Das T, et al. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci Transl Med 2016; 8: 327ra24–327ra24.
   Google Scholar
• Negrao MV, Quek K, Zhang J, et al. TRACERx: tracking tumor evolution to impact the course of lung cancer. J Thorac Cardiovasc Surg. 2018;155:1199–1202.
   PubMed Web of Science ®Google Scholar
• Jamal-Hanjani M, Hackshaw A, Ngai Y, et al. Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS Biol. 2014;12:e1001906.
   PubMed Web of Science ®Google Scholar
• Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non–small-cell lung cancer. N Engl J Med. 2017;376:2109–2121.
   PubMed Web of Science ®Google Scholar
• Siena S, Bardelli A, Sartore-Bianchi A, et al. Abstract A089: exploiting clonal evolution and liquid biopsy to overcome resistance to anti-EGFR treatment in metastatic colorectal cancer: the CHRONOS trial. Mol Cancer Ther. 2018;17:A089–A089.
   Web of Science ®Google Scholar
• Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21:795–801.
   PubMed Web of Science ®Google Scholar
• Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early stage lung cancer evolution. Nature. 2017;545:446–451.
   PubMed Web of Science ®Google Scholar
• Turajlic S, Xu H, Litchfield K, et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell. 2018;173:581–594.e12.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar